Arthur Klausner
Director/Board Member at MONOPAR THERAPEUTICS INC.
Net worth: 22 530 $ as of 2024-06-29
Arthur Klausner active positions
| Companies | Position | Start | End |
|---|---|---|---|
| MONOPAR THERAPEUTICS INC. | Director/Board Member | 2017-07-31 | - |
| Independent Dir/Board Member | 2017-07-31 | - | |
NYU Langone Health
 NYU Langone Health Packaged SoftwareTechnology Services NYU Elaine A. & Kenneth G. Langone Medical Center provides health care services. It offers treatments for bone, joint, and muscle disorders; brain and nervous system disorders cancers, tumors and blood disorders; genetic and chromosomal disorders and immune system disorders. The company was founded in 1841 and is headquartered in New York, NY. | Director/Board Member | - | - |
Concarlo Holdings LLC
 Concarlo Holdings LLC Miscellaneous Commercial ServicesCommercial Services Concarlo Holdings LLC operates as a biotechnology firm. It specializes in drug development. The company was founded by Stacy Blain and LisaMarie Casey and is headquartered in Brooklyn, NY. | Chairman | - | - |
Amyriad Therapeutics, Inc.
 Amyriad Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Amyriad Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. Amyriad Therapeutics, Inc. focuses on developing therapies for the relief of Alzheimer's disease symptoms. The company was founded by Christian Angermayer, Thomas Hanke, Anil K. Ratty, Marlon Braumann. The CEO is Sharon L. Rogers. | Director/Board Member | - | - |
| Delphinus Therapeutics, Inc. | Chief Executive Officer | 2017-12-31 | - |
| President | 2017-12-31 | - | |
Cennerv Pharmaceuticals Ltd.
 Cennerv Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cennerv Pharmaceuticals Ltd. engages in the pharmaceutical development specializing in CNS disorders with an initial focus on mental health such as depression, insomnia, dementia, schizophrenia and autism. The company was founded on July 13, 2015 and is headquartered in Singapore. | Director/Board Member | 2015-07-30 | - |
NYU Innovation Venture Fund
 NYU Innovation Venture Fund Investment ManagersFinance NYU Innovation Venture Fund, seeks investment opportunities in companies located in the United States. The fund targets start-up companies operating in the fields of information technology, computer software and biotechnology, especially by current NYU students, faculty, and researchers. It provides equity financing for seed capital requirements with an investment size ranging from USD 100,000 to 1 million. The fund does not invest in projects requiring further basic research. | Director/Board Member | - | - |
Career history of Arthur Klausner
Former positions of Arthur Klausner
| Companies | Position | Start | End |
|---|---|---|---|
Goldilocks Therapeutics, Inc.
 Goldilocks Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Goldilocks Therapeutics, Inc. engages in the development of drug delivery technology for kidney tubules. It offers treatment for acute kidney injury (AKI), polycystic kidney disease (PKD), and other under-treated kidney conditions by leveraging the Company’s proprietary mesoscale nanoparticles (MNPs). The company was founded by Arthur J. Klausner, Daniel A. Heller, and Edgar A. Jaimes in 2018 and is headquartered in Bedford, NY. | Director/Board Member | 2017-12-31 | 2021-12-31 |
| Chief Executive Officer | 2017-12-31 | 2021-12-31 | |
| Founder | 2017-12-31 | 2021-12-31 | |
| President | 2017-12-31 | 2021-12-31 | |
Gem Pharmaceuticals LLC
 Gem Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Gem Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company that develops anthracycline derivatives used to eliminate cardiotoxicity side effect in chemotherapeutics. The company is headquartered in Birmingham, AL. | Director/Board Member | 2011-12-31 | 2016-12-31 |
| Chief Executive Officer | 2011-12-31 | 2016-12-31 | |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Training of Arthur Klausner
| Princeton University | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Statistics
International
| United States | 17 |
| Singapore | 2 |
| 2 |
Operational
| Director/Board Member | 12 |
| Chief Executive Officer | 4 |
| President | 2 |
Sectoral
| Health Technology | 10 |
| Commercial Services | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| MONOPAR THERAPEUTICS INC. | Health Technology |
| Private companies | 14 |
|---|---|
Santarus, Inc.
 Santarus, Inc. Pharmaceuticals: MajorHealth Technology Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ. | Health Technology |
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
Gentis, Inc.
 Gentis, Inc. Medical SpecialtiesHealth Technology Gentis, Inc. engages in the development and testing technologies for the minimally invasive treatments. The company was founded by Charles Cohen and Paul Ducheyne in 2000 and is headquartered in Wayne, PA. | Health Technology |
Gem Pharmaceuticals LLC
Gem Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Gem Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company that develops anthracycline derivatives used to eliminate cardiotoxicity side effect in chemotherapeutics. The company is headquartered in Birmingham, AL. | Health Technology |
Jade Therapeutics, Inc.
 Jade Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kiora Pharmaceuticals, Inc., Jade Therapeutics, Inc. develops pharmaceutical products. The company is based in Salt Lake City, UT. The company was founded by Barbara Wirostko. Jade Therapeutics was acquired by Kiora Pharmaceuticals, Inc. on March 07, 2016 for $5.10 million. | Health Technology |
Pappas Capital LLC
 Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
Cennerv Pharmaceuticals Ltd.
Cennerv Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cennerv Pharmaceuticals Ltd. engages in the pharmaceutical development specializing in CNS disorders with an initial focus on mental health such as depression, insomnia, dementia, schizophrenia and autism. The company was founded on July 13, 2015 and is headquartered in Singapore. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
| Delphinus Therapeutics, Inc. | |
Goldilocks Therapeutics, Inc.
Goldilocks Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Goldilocks Therapeutics, Inc. engages in the development of drug delivery technology for kidney tubules. It offers treatment for acute kidney injury (AKI), polycystic kidney disease (PKD), and other under-treated kidney conditions by leveraging the Company’s proprietary mesoscale nanoparticles (MNPs). The company was founded by Arthur J. Klausner, Daniel A. Heller, and Edgar A. Jaimes in 2018 and is headquartered in Bedford, NY. | Commercial Services |
Amyriad Therapeutics, Inc.
Amyriad Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Amyriad Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. Amyriad Therapeutics, Inc. focuses on developing therapies for the relief of Alzheimer's disease symptoms. The company was founded by Christian Angermayer, Thomas Hanke, Anil K. Ratty, Marlon Braumann. The CEO is Sharon L. Rogers. | Health Technology |
Concarlo Holdings LLC
Concarlo Holdings LLC Miscellaneous Commercial ServicesCommercial Services Concarlo Holdings LLC operates as a biotechnology firm. It specializes in drug development. The company was founded by Stacy Blain and LisaMarie Casey and is headquartered in Brooklyn, NY. | Commercial Services |
NYU Langone Health
NYU Langone Health Packaged SoftwareTechnology Services NYU Elaine A. & Kenneth G. Langone Medical Center provides health care services. It offers treatments for bone, joint, and muscle disorders; brain and nervous system disorders cancers, tumors and blood disorders; genetic and chromosomal disorders and immune system disorders. The company was founded in 1841 and is headquartered in New York, NY. | Technology Services |
NYU Innovation Venture Fund
NYU Innovation Venture Fund Investment ManagersFinance NYU Innovation Venture Fund, seeks investment opportunities in companies located in the United States. The fund targets start-up companies operating in the fields of information technology, computer software and biotechnology, especially by current NYU students, faculty, and researchers. It provides equity financing for seed capital requirements with an investment size ranging from USD 100,000 to 1 million. The fund does not invest in projects requiring further basic research. | Finance |
- Stock Market
- Insiders
- Arthur Klausner
- Experience
